Apellis Pharmaceuticals Inc. has announced that five abstracts related to its drug SYFOVRE® (pegcetacoplan injection) have been accepted for oral presentation at the upcoming American Society of Retina Specialists (ASRS) Annual Scientific Meeting. The meeting is scheduled to take place from July 30 to August 2 in Long Beach, California. The presentations will highlight the efficacy and safety profile of SYFOVRE for patients with geographic atrophy (GA) secondary to age-related macular degeneration $(AMD)$. The data, to be presented by various specialists, will cover topics including baseline characteristics associated with GA progression, the impact of early versus delayed treatment, and the clinical utility of fellow eye data in bilateral GA cases. Additionally, a descriptive analysis of patients treated with pegcetacoplan and anti-VEGF, as well as the impact of AREDS oral micronutrient supplementation, will be discussed.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.